论文部分内容阅读
Antinori等最近比较了三种用药方案对197例HIV感染者预防卡氏肺孢子虫肺炎和弓形虫脑炎的效果。得出了氨苯砜能增加死亡率的结论。其根据是,接受氨苯砜-乙胺嘧啶处理的患者相对死亡率比复方新诺明处理组高2.8倍,而接受戊烷脒处理组的相对死亡率是复方新诺明处理组的2.2倍。本文作者对上述结论提出质疑,认为鉴于这种比较缺乏令人信服的统计学依据(P=0.07)以及观察样本较小,Antinori等人的结论是不恰当的,易给患者和医生造成思想上的混乱。
Antinori et al. Recently compared the efficacy of three regimens in preventing 197 Pneumocystis carinii pneumonia and Toxoplasma encephalitis in 197 HIV-infected individuals. Concluded that dapsone increased mortality. The basis for this is that the relative mortality in patients treated with dapsone plus pyrimethamine is 2.8-fold higher than in the cotrimoxazole-treated patients and 2.2-fold relative to the patients treated with pentamidine . The authors challenge the above conclusion and argue that Antinori et al.’s conclusion is inappropriate in view of the lack of convincing statistical grounds for this comparison (P = 0.07) and the observed sample size, which is apt to give patients and physicians ideological mess.